Drugs / Danegaptide
Danegaptide
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00820521 | Feb → Apr 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Withdrawn | No outcome recorded |
| Phase 1 | NCT00783341 | Nov 2008 → Feb 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00543946 | Oct 2007 → Mar 2008 | cardiac rhythm disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00510029 | Sep 2007 → Jan 2008 | cardiac rhythm disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01977755 Comparator | Nov 2013 → Dec 2015 | ST-elevation myocardial infarction | Zealand Pharma | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Danegaptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01977755 ↗ |
| Known as | Danegaptida | ChEMBL registry synonym — accepted as the source's own label CHEMBL560592 ↗ |
| Known as | GAP-134 | “Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Orally to Healthy Subjects” NCT00820521 ↗ |
| Known as | ZP-1609 | ChEMBL registry synonym — accepted as the source's own label CHEMBL560592 ↗ |
| Modality | Peptide | “This is a study of GAP-134, an antiarrhythmic di-peptide.” NCT00543946 ↗ |
| Route | Intravenous | “24-hr IV infusion” NCT00510029 ↗ |